{{Rsnum
|rsid=985162
|Chromosome=2
|position=129409778
|Orientation=minus
|GMAF=0.4605
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 46.2 | 44.6 | 9.2
| HCB | 15.6 | 46.7 | 37.8
| JPT | 0.0 | 40.9 | 59.1
| YRI | 1.6 | 31.7 | 66.7
| ASW | 0.0 | 0.0 | 0.0
| CHB | 15.6 | 46.7 | 37.8
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}

{{omim
|desc=ATTENTION DEFICIT-HYPERACTIVITY DISORDER, SUSCEPTIBILITY TO, 5
|id=612311
|rsnum=985162
}}

{{PharmGKB
|RSID=rs985162
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:18599010
|Annotation=rs985162 was found to be significantly linked to Motor timing in a Dutch population which is part of the International Multi-Center ADHD Genetics study.
|Drugs=
|Drug Classes=
|Diseases=Attention Deficit Disorder with Hyperactivity
|Curation Level=Curated
|PharmGKB Accession ID=PA162168108
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs985162
|overall_frequency_n=65
|overall_frequency_d=122
|overall_frequency=0.532787
|n_genomes=39
|n_genomes_annotated=0
|n_haplomes=57
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}